NEW YORK (TheStreet) -- The move by Cynapsus Therapeutics  (CYNA)  to list itself on the Nasdaq last month was more than an attempt to raise its visibility in the United States. It was also about raising enough capital to get it through some pivotal Phase 3 trials for its Parkinson's disease drug-delivery system, said CEO Anthony Giovinazzo.

"It brought us some very sophisticated investors from the United States who know this space quite well, which gives us some credibility," Giovinazzo said. "And we raised a substantial amount of money with the listing, which allows us to pursue the program we are currently embarked on."